Krintafel

Drug - Krintafel (tafenoquine) [GlaxoSmithKline LLC]

September 2019

Therapeutic area - Malaria

Approval criteria

Patient is at least 16 years or older AND
Patient has diagnosis of Plasmodium vivax malaria AND
Patient is receiving appropriate antimalarial therapy for acute P. vivax infection, for which it is susceptible (Krintafel is NOT indicated for the treatment of acute P. vivax malaria) AND
Krintafel will be used for the radical cure (prevention of relapse) of P. vivax AND
Patient does not have glucose-6-phosphate dehydrogenase (G6PD) deficiency (confirmed by testing) AND
Pregnancy status has been determined and, if pregnant, fetus does not have G6PD deficiency AND
If patient is breastfeeding, recipient child does not have G6PD deficiency AND
Patient does not have known hypersensitivity reactions to tafenoquine, other 8-aminoquinolines, or any component of Krintafel AND
Krintafel will be administered on the first or second day of antimalarial treatment for acute P. vivax infection AND
Patient has tried and failed primaquine for radical cure (prevention of relapse) of P. vivax

G6PD deficiency or unknown G6PD status
Breastfeeding woman if infant is found to be G6PD deficient or if G6PD status is unknown

2 tablets
An additional 2 tablets may be approved if patient vomited initial dose of 300 mg within 1 hour of administration (may be readministered once only)
No renewal will be approved

MHCP Provider Call Center 651-431-2700 or 800-366-5411